Investigating a protein's role in stroke treatment
Official title: Transient Receptor Potential Melastatin 2 (TRPM2) in Ischemic Stroke
Funded at University of Connecticut Sch of Med/dnt · NIH-10993195 · Data updated 2026-11-12
This study is looking at a protein called TRPM2 to see how it affects brain damage during a stroke, with the hope of finding new treatments that could help people recover better after a stroke.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Connecticut Sch of Med/dnt NIH-funded |
| Lab location | 1 site (Farmington, United States) |
| Project start | December 1, 2023 |
| Project end | November 30, 2028 |
| Funding year | 2025 |
| Award (this year) | $406,904 |
| NIH project number | 5R01NS131661-02 |
| Project ID | NIH-10993195 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals at risk of ischemic stroke or those who have experienced a stroke.
✕Less likely to help
Patients with hemorrhagic stroke or those with conditions unrelated to ischemic stroke may not benefit from this research.
What this research studies
This research focuses on understanding the role of the TRPM2 protein in ischemic stroke, a condition that leads to significant disability and death. The study aims to explore how TRPM2 contributes to the injury process during a stroke and whether it can be targeted for new therapies. By using both classical and clinically relevant animal models, the researchers hope to identify effective treatment strategies that could translate into better outcomes for stroke patients. The approach involves examining the complex interactions of various cell types and signaling pathways involved in stroke pathology.
Why it matters
Potential benefit: If successful, this research could lead to the development of new therapies that improve recovery and outcomes for stroke patients.
How similar studies have gone: While there have been many studies on stroke therapies, this approach targeting TRPM2 is relatively novel and has not been extensively tested in clinical settings.
Where this research is happening
-
University of Connecticut Sch of Med/dnt
Farmington, United States Active
Researchers
- Principal investigator: Yue, Lixia — University of Connecticut Sch of Med/dnt
- Study coordinator: Yue, Lixia
Related research
Other NIH-funded projects on the same topics.
-
Improving blood flow after stroke by breaking down NETs
Aims to see if breaking down neutrophil extracellular traps (NETs) after an ischemic stroke can improve blood flow and reduce brain injury in patients.
-
EP2 blockers to protect the brain after a stroke
Aims to test brain-permeable EP2 antagonists to reduce damage after ischemic stroke and improve recovery.
-
Genetic testing to find causes of early-onset ischemic stroke
This project uses whole-exome sequencing to look for gene changes that may cause ischemic stroke in adults who had a stroke at a young age.
-
Targeted nanomedicine to protect the brain after stroke
A targeted drug-delivery approach aims to boost blood-brain barrier repair and reduce brain damage after an acute ischemic stroke in patients at risk.
-
How biological aging and blood proteins relate to thinking after a stroke
This project looks at whether measures of biological aging and patterns of blood proteins help explain which stroke survivors keep their thinking sharp and which go on to develop vascular dementia.
-
Repurposing NEXLETOL to treat ischemic stroke
Aims to see if the cholesterol drug NEXLETOL can help people after an ischemic stroke by supporting brain energy use and reducing injury.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.